Bloxiverz(These highlights do not include all the information needed to use BLOXIVERZ safely and effectively. See full prescribing information for BLOXIVERZ. BLOXIVERZ (Neostigmine Methylsulfate Injection), for intravenous use Initial U.S. Approval: 1939)

Exela Pharma Sciences, LLC🇺🇸 United States

FDA Page

Effective Date: Dec 31, 2023
Approval ID: d2f55643-2b0d-4ef9-a9d8-b7138b314372
Products: 3 registered
Version: 18

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use BLOXIVERZ safely and effectively. See full prescribing information for BLOXIVERZ. BLOXIVERZ (Neostigmine Methylsulfate Injection), for intravenous use Initial U.S. Approval: 1939

Quick Stats

Total Products3

Labelers2

Label Sections20

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.